Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 22.39M P/E - EPS this Y 65.40% Ern Qtrly Grth -
Income -12.2M Forward P/E -1.43 EPS next Y -64.90% 50D Avg Chg -38.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -48.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -71.00%
Recommedations 1.50 Quick Ratio 0.35 Shares Outstanding 29.89M 52W Low Chg 9.00%
Insider Own 39.10% ROA -480.74% Shares Float 17.22M Beta 0.62
Inst Own 30.81% ROE - Shares Shorted/Prior 145.37K/112.45K Price 2.61
Gross Margin - Profit Margin - Avg. Volume 258,846 Target Price 8.75
Oper. Margin - Earnings Date Nov 12 Volume 23,507 Change -10.00%
About ProMIS Neurosciences Inc.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

ProMIS Neurosciences Inc. News
11/14/24 ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
11/12/24 ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
10/30/24 ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
09/12/24 ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
09/05/24 ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/08/24 ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
08/06/24 ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
08/01/24 ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
07/30/24 ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
07/26/24 ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
07/26/24 ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
05/14/24 ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
04/30/24 ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
04/09/24 ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
04/04/24 ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
04/01/24 ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
03/11/24 ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
02/22/24 ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
01/22/24 ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
01/08/24 ProMIS Neurosciences Issues Letter to Shareholders
PMN Chatroom

User Image youbi336 Posted - 2 days ago

$PMN The 10-Q form was a bit brutal. I'm long on this. What's your view of the financial situation here? Seems better than last year.

User Image d_risk Posted - 3 days ago

$PMN - ProMIS Neurosciences Inc. - 10Q - Updated Risk Factors Significant updates: PMN expresses doubt about its ability to continue as a going concern, needs more financing, and reports a material weakness in financial reporting controls. #Risk @ProMISinc https://d-risk.ai/PMN/10-Q/2024-11-14

User Image Sunny3999 Posted - 2 weeks ago

$PMN should fly soon

User Image BearishAlgo Posted - 10/31/24

$PMN end of day chart to track how the setup played out (white circle was entry zone)

User Image Simplrstonkies Posted - 10/31/24

$PMN gaining that volume! Slap that ask button! Let’s gooo!

User Image Simplrstonkies Posted - 10/31/24

$PMN $DRUG

User Image StreetwiseReports Posted - 10/31/24

Biotech Shares Positive Phase I Data for Alzheimer's Treatment: https://ow.ly/h5jI50TXvYV Leede Financial Inc.'s target price on ProMIS Neurosciences Inc. reflects a potential return of 822%. $PMN:TSX #biotechstocks

User Image Simplrstonkies Posted - 10/31/24

$PMN slap them asks! It’s still a major discount until it flys! 🚀

User Image youbi336 Posted - 10/31/24

$PMN

User Image youbi336 Posted - 10/31/24

$PMN So someone came in, bought lots of shares cheap and left the short sellers to bring this down

User Image Sunny3999 Posted - 10/31/24

$PMN Promis maB Alzheimer drug is worth at least 200m mcap and its just at 20m 10x soon

User Image Sunny3999 Posted - 10/31/24

$ADTX $PMN PMN has money till 2026

User Image Sunny3999 Posted - 10/31/24

$PMN wait for the power hour run 🔥🚀

User Image Boketaw Posted - 10/31/24

$PMN moving higher!! Long!!

User Image Bigmoney4me Posted - 10/31/24

$ADTX $PMN alzheimer’s !! raise there coming??

User Image BearishAlgo Posted - 10/31/24

$PMN potential shortsell MANAGE YOUR OWN RISK

User Image Sunny3999 Posted - 10/31/24

$PMN Europe investors notice the potential of this maB drug against Alzheimer Disease

User Image Sunny3999 Posted - 10/31/24

$PMN Ready to pop due to Alzheimer solution: https://www.promisneurosciences.com/news-media/press-releases/detail/232/promis-neurosciences-presents-positive-data-from-pmn310 @jacksparo @NewOldStock @davidstock @MomentumWhale @stockinstinct

User Image youbi336 Posted - 10/31/24

$PMN Why did this take off all of a sudden? The latest news is from yesterday

User Image Sunny3999 Posted - 10/31/24

$PMN Time to join for Alzheimer solution https://www.promisneurosciences.com/news-media/press-releases/detail/232/promis-neurosciences-presents-positive-data-from-pmn310 @Alejos11 @ACInvestorBlog @OpenOutcrier @topstockalerts @CrytiCaII @teambullish @PlayBookTrades @ZorTrades

User Image Sunny3999 Posted - 10/31/24

Link: https://www.promisneurosciences.com/news-media/press-releases/detail/232/promis-neurosciences-presents-positive-data-from-pmn310 $GILD $JNJ $MRK $PFE $PMN

User Image Sunny3999 Posted - 10/31/24

Link: https://www.promisneurosciences.com/news-media/press-releases/detail/232/promis-neurosciences-presents-positive-data-from-pmn310 $ABBV $AMGN $BMY $LLY $PMN

User Image Sunny3999 Posted - 10/31/24

$PMN Alzheimer disease solution NEWS: $RHHBY $NVS $SNY $AZN https://www.promisneurosciences.com/news-media/press-releases/detail/232/promis-neurosciences-presents-positive-data-from-pmn310

User Image Sunny3999 Posted - 10/31/24

$PMN News: Alzheimer solution in the making $ABBV $BMY $AMGN $LLY https://www.promisneurosciences.com/news-media/press-releases/detail/232/promis-neurosciences-presents-positive-data-from-pmn310

User Image Sunny3999 Posted - 10/31/24

$PMN This news is hot 🔥 $GILD $MRK $JNJ $PFE https://www.promisneurosciences.com/news-media/press-releases/detail/232/promis-neurosciences-presents-positive-data-from-pmn310

User Image intrader Posted - 10/30/24

$PMN

User Image intrader Posted - 10/30/24

$PMN I'm in.

User Image intrader Posted - 10/30/24

$PMN

User Image RonFarms Posted - 10/30/24

$PMN ^

User Image Will2ride1 Posted - 10/23/24

$PMN insider buying...yep📈👀

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Farfel Gail M Chief Executive Offi.. Chief Executive Officer Dec 14 Buy 4.94 1,000 4,940 2,000 12/16/22
Kirwin Patrick D. Director Director Dec 13 Buy 4.69 3,000 14,070 27,998 12/15/22
Williams Eugene Director Director Dec 07 Buy 5.4864 1,000 5,486 156,930 12/08/22
Farfel Gail M Chief Executive Offi.. Chief Executive Officer Dec 06 Buy 5.7 1,000 5,700 1,000 12/08/22
Williams Eugene Director Director Dec 02 Buy 5.98 1,000 5,980 155,930 12/06/22
Williams Eugene Chairman and CEO Chairman and CEO Jul 11 Buy 9.80 1,000 9,800 154,930 07/12/22